Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

4.17USD
23 Apr 2014
Price Change (% chg)

$-0.14 (-3.25%)
Prev Close
$4.31
Open
$4.34
Day's High
$4.36
Day's Low
$4.07
Volume
2,084,683
Avg. Vol
4,769,349
52-wk High
$6.95
52-wk Low
$1.68

NVAX.O

Chart for NVAX.O

About

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional... (more)

Overall

Beta: 1.10
Market Cap (Mil.): $901.03
Shares Outstanding (Mil.): 209.06
Dividend: --
Yield (%): --

Financials

  NVAX.O Industry Sector
P/E (TTM): -- 26.72 33.26
EPS (TTM): -0.31 -- --
ROI: -33.79 -2.48 18.95
ROE: -36.68 -11.48 19.72
Search Stocks

UPDATE 1-Experimental bird flu vaccines show promise in early trials

* Novartis, Novavax H7N9 vaccines give good immune response

14 Nov 2013

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF76.25 -0.15
Merck & Co., Inc. (MRK.N) $57.50 -0.27
Sanofi SA (SASY.PA) €77.05 -0.08
GlaxoSmithKline plc (GSK.L) 1,642.50p +2.50
AstraZeneca plc (AZN.L) 4,042.50p +82.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks